Agilent Technologies
A
$176.95
-0.52%
Agilent Technologies is a life sciences and diagnostics company, spun out of Hewlett-Packard in 1999, that sells analytical instrumentation, laboratory consumables, services, and diagnostic solutions across three segments: Life Sciences and Applied Markets, Agilent CrossLab, and Diagnostics and Genomics. It occupies a high-quality, wide-moat niche in the analytical lab equipment oligopoly, competing with Thermo Fisher and Waters, and derives over half of sales from sticky biopharma, chemical, and advanced materials end markets with a large recurring revenue base from consumables and services. The current investor narrative centers on a sharp operational turnaround: a strong quarterly beat and raised full-year profit forecast in late May 2026 triggered a step-change re-rating in the stock, and management is now leaning into high-margin pathology expansion via the Biocare Medical acquisition. Debate now hinges on whether the margin expansion and mid-single-digit-plus growth are durable against China exposure and biopharma funding cyclicality, with sell-side sentiment firmly constructive following a wave of reiterated Buy/Overweight ratings through the summer and fall.…
A
Agilent Technologies
$176.95
Related headlines
Investment Opinion: Should I buy A Today?
Rating: Hold (accumulate on weakness). Agilent is a high-quality, wide-moat analytical instruments franchise executing a genuine margin-driven turnaround — operating margin up ~293bps YoY to 23.64% and revenue up 8.06% to $1.878 billion in Q3 FY2026 — but at $174.76 the stock already discounts much of that improvement, leaving only +4.2% implied upside to the $182.05 average target despite a unanimous 'buy' consensus (15 Buy, 7 Hold, 0 Sell; mean 1.77). The thesis is sound; the entry price is not compelling.
Supporting evidence is strong on fundamentals: three consecutive quarters of sequential margin expansion (gross margin 52.61% → 54.99% → 55.48%; operating margin 19.63% → 21.74% → 23.64%), TTM free cash flow of $1.436 billion (~3.5% FCF yield on the ~$41.4 billion market cap) against just $80 million of quarterly capex, ROE of 19.33%, and a manageable 0.498 debt-to-equity with a 1.957 current ratio. Forward EPS of $9.10 versus trailing PE of 31.89x and forward PE of 26.01x implies ~18% earnings growth is already capitalized, and the 5.96x PS and 23.43x EV/EBITDA sit at the premium end of the stock's own 2025 range (23.9x-24.1x trailing PE). The $200 high target (+14%) requires sustained margin expansion plus clean Biocare integration; the $155 low target (-11%) prices in exactly the China/biopharma and integration risks that would invalidate the bull case.
Three risks could break the thesis: (1) margin durability — if operating margin stalls below 23%, the 31.89x multiple compresses toward the mid-20s and the stock retests the $140s; (2) China and biopharma funding cyclicality, which the $155 low target explicitly discounts; (3) Biocare integration, where the $950 million outlay plus $599 million of debt repayment already drove a $49 million net cash decline in Q3. This Hold would upgrade to Buy on a pullback toward the $155-$160 support zone (implying ~26x forward EPS) or on evidence that gross margin holds above 55% into FY2027; it would downgrade to Sell if operating margin slips below 21% or forward revenue guidance drops below the $9.37 billion consensus. Verdict: fairly valued to modestly rich relative to its own history — a quality compounder priced for continued execution, not a bargain.
Sign up to view all
A 12-Month Price Forecast
Agilent is a fundamentally improving franchise — 8.06% revenue growth, ~300bps of operating margin expansion, and $1.436 billion of TTM free cash flow — but the market has already paid for it, with the stock up 51.15% in six months and trading at 31.89x trailing earnings near the top of its multi-year band. The unanimous sell-side camp (15 Buy, 7 Hold, 0 Sell) with a $182.05 average target implies only +4.2% upside, signaling the Street sees fair value near current levels and further gains as dependent on continued beats rather than multiple re-rating. The key tension is whether the margin expansion is structural or cyclical: durable ~300bps of operating leverage through Biocare integration justifies the premium and supports a grind toward $200, while any compression toward 21% would expose the PEG of 9.44 and pull the stock toward $155. I would upgrade to bullish on a pullback into the $155-$165 zone (roughly 26x forward EPS) or on a fourth consecutive quarter of margin expansion with FY2027 guidance above consensus; I would downgrade to bearish if operating margin slips below 21% or China/biopharma demand visibly rolls over.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Agilent Technologies's 12-month outlook, with a consensus price target around $182.05 and implied upside of +2.9% versus the current price.
Average Target
$182.05
22 analysts
Implied Upside
+2.9%
vs. current price
Analyst Count
22
covering this stock
Price Range
$155 - $200
Analyst target range
Coverage is broad and overwhelmingly constructive: 20 analysts cover Agilent with 15 Buy ratings, 7 Hold ratings, and zero Sells, yielding a consensus recommendation of "buy" (mean rating of 1.77 on a 1-5 scale where lower is more bullish). The average target price of $182.05 implies roughly +4.2% upside from the current $174.76 — a modest gap that reflects how much of the bull case is already priced in after the stock's 51% six-month run. The consensus leans clearly bullish on direction but the thin implied upside suggests the Street views the stock as fairly valued near current levels, with further gains dependent on continued earnings beats rather than multiple re-rating. The target range spans $155 (low) to $200 (high), a spread of about 29% around the average that signals moderate — not extreme — dispersion in analyst conviction. The $200 high target implies roughly 14% upside and likely assumes sustained margin expansion, successful Biocare integration into high-margin pathology, and continued double-digit relative outperformance; the $155 low target, about 11% below the current price, would price in margin compression, China/biopharma funding headwinds, or integration missteps. Institutional ratings show a consistent pattern of reiterated Buy/Overweight calls from Morgan Stanley, TD Cowen, Barclays, Wells Fargo, JP Morgan, Citigroup, BofA, Goldman Sachs, and Stifel through August-October 2026 with no downgrades — a stable, high-conviction bull camp, though the absence of fresh upgrades suggests the easy re-rating has already occurred.
Drowning in data?
Find the real signal!
Bulls vs Bears: A Investment Factors
The bull case currently holds the stronger evidence: three consecutive quarters of margin expansion (operating margin up ~293bps YoY to 23.64%), 8.06% revenue growth, $1.436 billion of TTM free cash flow, and unanimous sell-side support with zero Sells. The bear case rests less on fundamentals than on price — a 31.89x trailing PE near the top of its multi-year band and only +4.2% implied upside to the average target mean much of the good news is already discounted. The single most important tension is whether the margin expansion is structural or cyclical: if the ~300bps of operating leverage proves durable through Biocare integration and China/biopharma demand holds, the premium multiple is justified and the stock can grind toward the $200 high target; if margins compress even modestly, the PEG of 9.44 offers no cushion and the stock could retrace toward the $155 low target. Momentum and relative strength (+24.6 over three months versus a falling S&P 500) are genuine, but they are also the reason the risk/reward for new capital is far less favorable than it was at the May breakout.
Bullish
- Operating leverage driving margin expansion: Operating margin climbed to 23.64% in Q3 FY2026 from 20.71% a year earlier, a roughly 293bps year-over-year improvement, while gross margin rose to 55.48% from 52.59%. The sequential cadence (gross margin 52.61% → 54.99% → 55.48%; operating margin 19.63% → 21.74% → 23.64%) shows textbook operating leverage as revenue scales.
- Revenue re-accelerating to 8.06% YoY: Q3 revenue of $1.878 billion grew 8.06% year-over-year versus $1.738 billion, with sequential growth of $1.798B → $1.835B → $1.878B through fiscal 2026. Consensus forward revenue of $9.368 billion implies continued mid-to-high-single-digit expansion, shifting the narrative from cyclical recovery to durable compounder.
- Recurring revenue mix anchors visibility: Agilent CrossLab, the consumables-and-services franchise, is the largest segment at $786 million of Q3's $1.878 billion, providing sticky recurring revenue. Over half of sales come from biopharma, chemical, and advanced materials end markets, which are structurally the most defensible customer bases.
- Strong cash generation and balance sheet: TTM free cash flow of $1.436 billion against a ~$41.4 billion market cap implies a ~3.5% FCF yield, with quarterly operating cash flow of $519 million versus just $80 million of capex (6.5x coverage). Debt-to-equity of 0.498 and a current ratio of 1.957 leave ample room to absorb the $950 million Biocare acquisition.
Bearish
- Valuation full at 31.9x trailing earnings: The trailing PE of 31.89x sits above the mid-to-high-20s range seen through much of 2025 (23.9x at Q4 2025, 24.1x at Q2 2026) and far above the 15.9x trough in late 2023. The PEG ratio of 9.44 and 5.96x PS ratio leave little room for execution missteps.
- Thin analyst upside after 51% run: The $182.05 average target implies only +4.2% upside from $174.76, and the stock already trades at ~89% of its 52-week range ($108.35-$182.99). The absence of fresh upgrades suggests the easy re-rating has already occurred and further gains require continued beats.
- China and biopharma funding cyclicality: Agilent's geographic concentration includes China as one of its two largest country markets, exposing it to geopolitical and stimulus-driven demand swings. Biopharma funding cycles directly affect the stickiest end market, and the $155 low analyst target (~11% below current) prices in exactly these headwinds.
- Biocare integration execution risk: The $950 million Biocare Medical acquisition plus $599 million of debt repayment consumed cash in Q3, driving a $49 million net cash decline. The pathology expansion thesis depends on successful integration into high-margin diagnostics, and any misstep would undercut the margin-expansion narrative.
A Technical Analysis
Agilent is in a powerful, sustained uptrend, with the stock up 18.49% over the past year and an extraordinary 51.15% over six months, decisively outperforming the S&P 500's 9.59% and -0.54% respective returns. At $174.76, the stock sits at roughly 89% of its 52-week range ($108.35 low to $182.99 high), just below the upper boundary — a positioning that signals strong momentum but also meaningful extension risk after such a steep run. The trend structure is clearly bullish, with higher highs and higher lows since the May breakout, though the proximity to the 52-week high means the risk/reward for new entries is less favorable than it was six months ago. Short-term momentum remains positive but is decelerating relative to the torrid mid-year pace: the 1-month gain of 3.35% and 3-month gain of 19.72% compare to the 51.15% six-month surge, indicating the rate of advance is cooling as the stock consolidates near highs. Notably, this relative strength is occurring against a weak tape — the S&P 500 fell 4.99% over the past month and 4.91% over three months — producing relative strength readings of +8.34 (1-month) and +24.63 (3-month), evidence of genuine idiosyncratic demand rather than beta-driven drift. The recent pullback from the $181.48 late-October high to $174.76 looks like orderly profit-taking within an intact uptrend rather than distribution, though the 2.98-point single-day gain on the latest session shows buyers remain active on dips. Key resistance sits at the 52-week high of $182.99; a clean breakout above that level would confirm trend continuation and likely invite momentum-driven flows, while support is anchored at the 52-week low of $108.35, with intermediate support likely in the $160-$165 zone where the September breakout originated. With a beta of 1.237, Agilent is roughly 24% more volatile than the market, and a max drawdown of -29.87% underscores that this is not a defensive holding — position sizing should account for amplified downside in risk-off regimes, and the short ratio of 2.03 suggests no meaningful bearish crowding to fuel a squeeze either way.
Beta
1.24
1.24x market volatility
Max Drawdown
-29.9%
Largest decline past year
52-Week Range
$108-$183
Price range past year
Annual Return
+18.4%
Cumulative gain past year
| Period | A Return | S&P 500 |
|---|---|---|
| 1m | +3.3% | -2.4% |
| 3m | +18.5% | -2.3% |
| 6m | +58.4% | +2.8% |
| 1y | +18.4% | +11.3% |
| ytd | +28.3% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
A Fundamental Analysis
Agilent's revenue trajectory is re-accelerating: the most recent quarter (ended 2026-07-31) delivered $1.878 billion in revenue, up 8.06% year-over-year versus $1.738 billion in the prior-year Q3, and the sequential cadence of $1.798B (Q1) → $1.835B (Q2) → $1.878B (Q3) shows steady, compounding growth through fiscal 2026. Segment data for the quarter shows Agilent CrossLab at $786 million, Life Sciences and Applied Markets at $746 million, and Applied Markets at $346 million, with the recurring CrossLab consumables-and-services franchise the largest contributor — a structurally attractive mix that supports visibility. The growth trend implies the investment case is transitioning from a cyclical recovery story to a durable mid-to-high-single-digit compounder, and consensus revenue estimates of $9.368 billion for the forward period reinforce expectations of continued expansion. Profitability is robust and expanding: Q3 net income reached $362 million on a 55.48% gross margin, up from $336 million and a 52.59% gross margin in the year-ago quarter, while operating margin climbed to 23.64% from 20.71%. The sequential margin progression — gross margin of 52.61% (Q1) → 54.99% (Q2) → 55.48% (Q3) and operating margin of 19.63% → 21.74% → 23.64% — is a textbook demonstration of operating leverage, with net margin rising to 19.28% from 16.96% in Q1. These margins are consistent with a premium instrumentation franchise, and the direction of travel (roughly 300bps of operating margin expansion year-over-year) is the single most important fundamental driver behind the stock's re-rating. The balance sheet and cash generation are solid: debt-to-equity of 0.498 is moderate, the current ratio of 1.957 indicates ample liquidity, and TTM free cash flow of $1.436 billion against a $41.4 billion market cap implies a roughly 3.5% FCF yield. ROE of 19.33% and ROA of 8.63% confirm efficient capital deployment, and quarterly operating cash flow of $519 million with capex of just $80 million (a 6.5x capex coverage ratio) shows the business funds itself internally. The main watch item is the $950 million of acquisitions in Q3 (Biocare) plus $599 million of debt repayment, which consumed cash and drove a modest $49 million net cash decline — worth monitoring for integration execution, but not a balance-sheet concern given the $1.76 billion cash position.
Quarterly Revenue
$1.9B
2026-07
Revenue YoY Growth
+8.1%
YoY Comparison
Gross Margin
55.5%
Latest Quarter
Free Cash Flow
$1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is A Overvalued?
Because Agilent is solidly profitable (Q3 net income of $362 million; TTM net margin of 18.75%), the PE ratio is the appropriate primary metric. The stock trades at 31.89x trailing earnings but only 26.01x forward earnings — a roughly 18% compression that signals the market expects meaningful EPS growth, consistent with consensus forward EPS of $9.10 versus the depressed trailing figure. The PEG ratio of 9.44 is elevated and warrants caution, though it is distorted by a low near-term growth denominator rather than reflecting an inherently overvalued franchise. Relative to its own history, the current 31.89x trailing PE sits above the mid-20s to high-20s range seen through much of 2025 (e.g., 23.9x at Q4 2025 and 24.1x at Q2 2026) and well above the 15.9x trough in late 2023, placing it toward the upper end of its multi-year band. The forward multiple of 26.0x is more moderate and suggests the market is pricing in continued margin-driven EPS expansion rather than pure multiple expansion. On other measures, the 5.96x PS ratio and 23.43x EV/EBITDA are premium but not extreme for a high-margin, wide-moat life sciences tools franchise, while the 6.14x P/B reflects a capital-light, high-ROE business model. The valuation is best characterized as full but defensible: it embeds optimistic assumptions about sustained margin expansion and Biocare integration, leaving limited room for execution missteps, and the premium versus the broader market is justified only if the current growth and margin trajectory persists.
PE
31.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~37x
vs. Industry Avg
35.2x
Industry PE ~35.2x*
EV/EBITDA
23.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the durability of the margin story and the cash cost of M&A. The ~293bps of year-over-year operating margin expansion to 23.64% is the pillar of the re-rating, so any reversal — whether from mix shift, pricing pressure, or Biocare dilution — would hit both earnings and multiple simultaneously. The $950 million Biocare acquisition plus $599 million of debt repayment drove a $49 million net cash decline in Q3, and while the $1.76 billion cash position and 0.498 debt-to-equity keep this manageable, integration missteps in a high-margin pathology market would be costly. Revenue concentration adds another layer: CrossLab at $786 million is the largest segment, and over half of sales depend on biopharma, chemical, and advanced materials spending, which is cyclical and funding-sensitive. Finally, the trailing PE of 31.89x versus forward 26.01x means the market is already capitalizing expected EPS growth to $9.10, so a single earnings miss would compress the multiple on a lower base. Market and competitive risks are dominated by valuation compression and end-market cyclicality. At 31.89x trailing earnings, 5.96x sales, and 23.43x EV/EBITDA, Agilent trades at a premium to its own 2025 history (23.9x-24.1x) and needs continued beats to justify the multiple; the PEG of 9.44 highlights how little growth is embedded relative to price. Competition from Thermo Fisher and Waters in the analytical instruments oligopoly limits pricing power, while China exposure and biopharma funding cycles introduce demand volatility that the $155 low analyst target explicitly discounts. The beta of 1.237 means a broad risk-off move amplifies losses, and with the S&P 500 down 4.99% over the past month, sector rotation out of premium healthcare names is a live threat. The Biocare pathology push is strategically sound but puts Agilent into a new competitive arena where execution, not incumbency, determines outcomes. The worst-case scenario is a margin-compression and multiple-de-rating double hit. If Q4 or FY2027 guidance shows operating margin stalling below 23% and China/biopharma demand softening, the market could reprice the stock from 31.9x toward its 2025 mid-20s multiple, which on trailing EPS alone implies a price near the $140s. Layering in the $155 analyst low target (~11% below current) and the 52-week low of $108.35 (~38% below current), a realistic adverse path runs from -11% to -38%, with the -29.87% historical max drawdown a useful midpoint reference. An investor at $174.76 could therefore lose roughly 11% in a mild de-rating and up to ~38% in a severe scenario where Biocare integration disappoints and end-market demand rolls over simultaneously.
FAQ
Ranked by severity: first, margin durability — the ~293bps of operating leverage to 23.64% is the pillar of the re-rating, and any slip below 23% would hit earnings and multiple simultaneously, with the 31.89x trailing PE offering no cushion. Second, end-market cyclicality — China is one of Agilent's two largest country markets and over half of sales depend on biopharma, chemical, and advanced materials spending, exactly the headwinds the $155 low target discounts. Third, integration and cash deployment — the $950 million Biocare acquisition plus $599 million of debt repayment drove a $49 million net cash decline in Q3, so pathology execution is now a live variable. Fourth, market-structure risk — a beta of 1.237 makes the stock roughly 24% more volatile than the market, and with the S&P 500 down 4.99% over the past month, rotation out of premium healthcare names could amplify any pullback toward the -29.87% historical max drawdown.
The base case (50% probability) targets $175-$185, anchored on the $182.05 average analyst target and assuming 7-8% revenue growth in line with the $9.368 billion consensus, operating margin holding in the 23-24% band, and a forward multiple near 26x. The bull case (25%) targets $190-$200, requiring operating margin toward the mid-20s, accretive Biocare pathology revenue, China stimulus, and a biopharma funding recovery that breaks the stock above its $182.99 52-week high toward the $200 high target. The bear case (25%) targets $155-$165, driven by margin slipping toward 21%, China or biopharma demand softening, and multiple compression toward the mid-20s. The base case is most likely: the stock consolidates near fair value as earnings growth, not multiple expansion, does the work.
Agilent screens as fairly valued to modestly rich relative to its own history. The 31.89x trailing PE sits above the 23.9x-24.1x range seen through much of 2025 and far above the 15.9x trough in late 2023, placing it near the top of its multi-year band. The forward PE of 26.01x on $9.10 consensus EPS is more moderate and implies roughly 18% earnings growth is already capitalized, while the 5.96x PS, 23.43x EV/EBITDA, and 6.14x P/B are premium but not extreme for a high-margin, wide-moat life sciences tools franchise. The 9.44 PEG ratio is the loudest warning sign, though it is distorted by a low near-term growth denominator. The market is paying for continued margin expansion and clean Biocare integration — not for a bargain.
The risk/reward is balanced rather than compelling at $174.76. On the positive side, Agilent has delivered three consecutive quarters of sequential margin expansion (operating margin 19.63% → 21.74% → 23.64%), 8.06% revenue growth to $1.878 billion, and $1.436 billion of TTM free cash flow, with 15 Buy and 0 Sell ratings among 20 analysts. On the negative side, the $182.05 average target implies only +4.2% upside, and the stock already sits at roughly 89% of its 52-week range after a 51.15% six-month run. The biggest downside risk is a margin stall that compresses the 31.89x trailing multiple toward the mid-20s, which would pull the stock toward the $155 low target (-11%) or worse. It is a good buy for long-horizon investors who can accumulate in the $155-$165 zone near 26x forward EPS, but at current levels it is closer to a hold than a fresh entry.
Agilent is better suited to a long-term hold of at least 12-24 months than to short-term trading. The business is a mid-to-high-single-digit revenue compounder with sticky recurring revenue from CrossLab consumables and services, 19.33% ROE, and $1.436 billion of TTM free cash flow, which supports multi-year compounding but offers little explosive upside. The 0.68% dividend yield and 0.216 payout ratio mean returns come almost entirely from earnings growth and multiple stability, not income. Short-term traders face a 1.237 beta, a -29.87% max drawdown, and a stock already extended at 89% of its 52-week range after a 51.15% six-month surge, making near-term entry timing unusually risky. A sensible minimum holding period is 18-24 months, ideally entered on a pullback toward the $155-$165 support zone.